Recent studies have shown that overexpression of SHMT2 is observed in a variety of cancers, including breast, melanoma, lung, ovarian, and prostate cancers (Anderson et al. 2011; Ding et al. 2013; Lee et al. 2014), and that it is associated with tumorigenesis and progression. This evidence concerns the gene SHMT2 and cancer.